US5489575A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Polypeptides and their use
Assignee: Angiogenetics Sweden AB
•
Filing: 1992-06-10
•
Granted: 1996-02-06
•
Expires: 2012-06-10
Abstract
Abstract Polypeptides comprising the following amino acid sequence: Arg-Arg-Arg-Pro-Arg-Pro-Pro-Tyr-Leu-Pro-Arg-Pro-Arg-Pro-Pro-Pro-Phe-Phe-Pro-Pro-Arg-Leu-Pro-Pro-Arg-Ile-Pro-Pro-Gly-Phe-Pro-Pro-Arg-Phe-Pro-Pro-Arg-Phe-Pro; pharmaceutical compositions containing such polypeptides; and a method of inhibiting bacterial growth using such polypeptides.
Inventors
- 👤 Jong-Youn Lee
- 👤 Hans G. Boman
- 👤 Viktor Mutt
- 👤 Hans Jornvall
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:46
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; C07K14/4701; C07K14/4723; A; A61; A61P; A61P31/00; A61P31/04; A61K; A61K38/00
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
15 words
A bacteriocidal polypeptide which comprises a polypeptide consisting of the following amino acid sequence: Arg-Arg-Arg-Pro-Arg-Pro-Pro-Tyr-Leu-Pro-Arg-Pro-Arg-Pro-Pro-Pro-Phe-Phe-Pro-Pro-Arg-Leu-Pro-Pro-Arg-Ile-Pro-Pro-Gly-Phe-Pro-Pro-Arg-Phe-Pro-Pro-Arg-Phe-Pro.
Claim 2
Dependent Claim
15 words
A bacteriocidal polypeptide which comprises a polypeptide consisting of the following amino acid sequence: Arg-Arg-Arg-Pro-Arg-Pro-Pro-Tyr-Leu-Pro-Arg-Pro-Arg-Pro-Pro-Pro-Phe-Phe-Pro-Pro-Arg-Leu-Pro-Pro-Arg-Ile-Pro-Pro-Gly-Phe-Pro-Pro-Arg-Phe-Pro-Pro-Arg-Phe-Pro.
Claim 3
Dependent Claim
10 words
A polypeptide consisting of the amino sequence of claim 1.
Claim 4
Dependent Claim
40 words
A pharmaceutical composition containing as a bacteriocidal constituent a polypeptide according to claim 1 wherein said bacteriocidal polypeptide is contained in an amount sufficient to kill bacteria or to inhibit bacterial growth together with a pharmaceutically acceptable carrier or diluent.
Claim 5
Dependent Claim
21 words
A pharmaceutical composition according to claim 3, wherein said carrier or diluent is acceptable for oral, intramuscular, intravenous or subcutaneous administration.
Claim 6
Dependent Claim
40 words
A method for killing bacteria or inhibiting bacterial growth in a mammalian organism, comprising administering in an amount of a polypeptide according to claim 1 which is sufficient to kill bacteria or to inhibit bacterial growth in said mammalian organism.
Claim 7
Dependent Claim
27 words
A method according to claim 5 orally administering a composition containing said polypeptide in a slow release dose form together with a pharmaceutically acceptable carrier or diluent.
Claim 8
Dependent Claim
42 words
A method according to claim 5, comprising administering by injection a composition containing said polypeptide in an amount sufficient to kill bacteria or to inhibit the growth of bacteria in an injectable dose form together with a pharmaceutically acceptable carrier or diluent.
Claim 9
Dependent Claim
39 words
A pharmaceutical composition containing as a bacteriocidal constituent the polypeptide according to claim 2 wherein said polypeptide is contained in an amount sufficient to kill bacteria or to inhibit bacterial growth together with a pharmaceutically acceptable carrier or diluent.
Claim 10
Dependent Claim
20 words
A method for killing bacteria or inhibiting bacterial growth according to claim 5 wherein said mammalian organism is a human.
Claim 11
Dependent Claim
33 words
A method for killing bacteria or inhibiting bacterial growth in a mammalian organism, comprising administering a polypeptide according to claim 2 in an amount sufficient to kill bacteria or to inhibit bacterial growth.
Claim 12
Dependent Claim
33 words
A method for killing bacteria or inhibiting bacterial growth in a mammalian organism, comprising administering a composition according to claim 3 in an amount sufficient to kill bacteria or to inhibit bacterial growth.
Claim 13
Dependent Claim
33 words
A method for killing bacteria or inhibiting bacterial growth in a mammalian organism, comprising administering a composition according to claim 4 in an amount sufficient to kill bacteria or to inhibit bacterial growth.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-02-05 | 1999-08-07 | 2000-02-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-02-05 | 2003-08-07 | 2004-02-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-02-05 | 2007-08-07 | 2008-02-06 | $7700.00 | Window Closed / Lapsed |